Results: IPMC involved >5% of villi in 11 of 17 placentas (65%) from FD cases, but only 1 of 118 from live births (0.8%, p<0.0001). IPMC involved >10% of villi in 5 of 17 placentas (30%) from FD cases and none from live births (0%, p<0.0001). Clinical data for 11 of the 17 FD cases was available. IPMC in >5% of villi were seen in 3 of the 7 cases where fetus was delivered within 1 day, versus 4 of 4 cases where fetus was retained for >1 days after demise (p<.05). Frequency of IPMC in categories other than fetal demise are shown in table 1. Figures 1 and 2: IPMC in the basement membranes of villi with perivillous fibrin and within the perivillous fibrin (1A and 1B). However, IPMC were also present in otherwise seemingly normal villi, without any perivillous fibrin (2A).
Percentage of Villi involved by IPMC (%)
Chorioamnionitis (n=19), n(%) GDM (n=20), n(%) Figures 1 and 2: IPMC in the basement membranes of villi with perivillous fibrin and within the perivillous fibrin (1A and 1B). However, IPMC were also present in otherwise seemingly normal villi, without any perivillous fibrin (2A).
Conclusions:
Association of IPMC with fetal demise, duration of fetal demise and perivillous fibrin suggests that IPMC may be a response to a local hypoxic environment. Presence of IPMC in more than 10% of villi may be used to support a diagnosis of intrauterine fetal demise in forensic and medico-legal cases.
Results: Four cases of cutaneous MASC were identified. The tumors arose in two men and two women patients ranging from 24 to 71 in age (mean, 49 years). The cases presented in the axillary skin (n=2), ventral neck (n=1), and skin of the cheek (n=1). The tumors arose in the superficial dermis in association with adnexal structures, with no breast or salivary tissue within the specimen. Moreover, none of the patients had a history of precedent breast or salivary gland tumors. The neoplasms exhibited histologic features classic for MASC: circumscribed but unencapsulated proliferations of bland, eosinophilic cells arranged in microcysts and follicles. Intraluminal secretions were seen in all cases, and 3 of 4 demonstrated prominent intratumoral sclerosis. By immunohistochemistry, all cases were diffusely positive for S100 and mammaglobin. Finally, all cases harbored rearrangements of ETV6 as demonstrated by FISH. All tumors were treated by simple excision alone. Follow up was available in 2 of 4, with no reported recurrences or metastases. Conclusions: True MASC may rarely occur in the skin, where it likely arises from adnexal structures. Cutaneous MASC appears to be histologically, immunophenotypically, and even genetically identical to their mammary and salivary counterparts, complete with ETV6 rearrangements. An awareness of this cutaneous tumor type is needed to avoid diagnostic confusion, as it may unfamiliar to many dermatopathologists. Additional cases with follow-up are needed to determine the prognostic significance of cutaneous MASC.
Human Papillomavirus and Activating EGFR Mutations: Alternative Oncogenic Mechanisms in Inverted Sinonasal Papilloma
Noah Brown, Aaron Udager, Jonathan McHugh, Thomas E Carey. University of Michigan Health System, Ann Arbor, MI. Background: Inverted sinonasal papillomas (ISP) are benign tumors of the sinonasal tract. The oncogenesis of these tumors is currently unknown, however, human papillomavirus (HPV) infection has been proposed to play a role. Recently, we identified activating somatic EGFR mutations in nearly 90% of ISP, suggesting that EGFR pathway activation is central to ISP oncogenesis. Interestingly, HPV infection can also stimulate EGFR pathway activation via E5 oncoprotein activity. Thus, we sought to explore the relationship between HPV infection and somatic EGFR mutations in ISP. Design: 21 cases of ISP were identified retrospectively from the pathology records database at a single large academic institution, and after central review by an experienced head and neck pathologist, representative formalin-fixed, paraffin-embedded tissue from each case was selected for sequencing. Sanger sequencing of EGFR exons 18-21 was performed with nested sequencing primers. Detection of HPV DNA was performed using two methods: 1) Sanger sequencing with the PGMY 09/11 L1 consensus primer set; and, 2) PCR-based mass spectrometry for high risk subtypes (i.e., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73) . Results: EGFR mutations were identified in 19 (90.5%) cases. HPV DNA was detected in 3 (14.3%) cases, including 2 cases with HPV subtype 11 and 1 case with HPV subtype 6; no high risk subtypes were detected. 19/19 (100%) of HPV-negative cases harbored an EGFR mutation, and 2/3 (66.7%) of HPV-positive cases were EGFR wild type; only one case had both HPV DNA (subtype 11) and an EGFR mutation (E746_S752delinsT). Overall, the detection of HPV DNA and EGFR mutations showed strong, negative correlation (phi coefficient = -0.79, P = 0.014).
Conclusions: This is the first report to investigate HPV infection and somatic EGFR mutations in ISP, and our data demonstrate strong, negative correlation between HPV DNA and EGFR mutations in these tumors. These results suggest that either somatic EGFR mutation or HPV infection is a primary oncogenic event in the vast majority of ISP, although rare tumors (<5%) may harbor both HPV DNA and an EGFR mutation. Furthermore, our data support the hypothesis that EGFR pathway activation is a central event in ISP oncogenesis, which may have important implications for treatment of advanced, surgically unresectable tumors.
Detection of HPV-DNA from May-Grünvald-Giemsa Stained FineNeedle Aspiration Specimens Using Polymerase Chain Reaction
Hani I Channir, Christian G Larsen, Lise Ahlborn, Thomas van Overeem Hansen, Thomas A Gerds, Birgitte W Charabi, Ben Vainer, Christian von Buchwald, Christel B Lajer, Katalin Kiss. Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; University of Copenhagen, Copenhagen, Denmark. Background: Human Papillomavirus (HPV)-related non-keratinizing oropharyngeal squamous cell carcinomas (NKOPSCC) often present with cystic cervical metastasis, and can be diagnostic challenging for the pathologists. In addition, the detection of HPV-DNA on fine-needle aspiration (FNA) specimens could potentially be a useful tool in the diagnostic workup of patients with metastases from unknown primary to the neck. The objective of this study was to assess the ability to detect HPV-DNA using Polymerase Chain Reaction (PCR) essay on scraped cells from previously May-Grünvald-Giemsa (MGG)-stained FNA smears and their corresponding histological specimens. Design: We collected archived MGG stained FNA smears and the corresponding surgical specimens from metastases and primary tumors from 51 patients with NKOPSCC, 12 with oral squamous cell carcinomas (OSCC), and 20 with branchial cleft cysts and 20 with Warthin tumors. A single representative FNA slide from each case was chosen. The coverslips from FNA smears were removed and all material from the object glass was scraped off with a sterile scalpel. The scraped cell material and the corresponding formalin fixed paraffin embedded histological specimens were analyzed for HPV-DNA by PCR. p16 immunohistochemistry was performed on the surgical specimens of the carcinomas.
Results:
The surgical specimen from all primary NKOPSCC and their metastases were both p16 and HPV-DNA positive. HPV-DNA was found in 49 of the corresponding FNA from the metastases. The two HPV negative FNA-specimens contained less than 50 well preserved epithelial cells. The 12 OSCCs and the FNA from their metastases were HPV-DNA negative. All histologic samples from these tumors were p16-negative.
There was no detectable HPV-DNA neither in the FNA nor the corresponding surgical specimens from the Warthin tumors and the branchial cleft cysts. Conclusions: HPV-DNA detection by PCR-essay from previously MGG stained FNAspecimens is a useful diagnostic tool and can improve the work-up program for patients presenting with metastasis to the neck.
PSMA Expression in Non-Neoplastic and Neoplastic Salivary Gland
Esther Cheng, Neil H Bander, Brian D Robinson, Theresa Scognamiglio. Weill Cornell Medical College, New York, NY. Background: Prostate specific membrane antigen (PSMA) is expressed in benign and malignant prostate and the neovasculature of most solid tumors. As such, it has become a novel target for therapy in prostate cancer and solid tumors. PSMA also shows low levels of expression in small intestine, renal tubular cells, and salivary gland. In this study, we aimed to analyze the distribution and expression of PSMA in salivary gland tumors and normal salivary gland and evaluate the use of PSMA as a potential diagnostic and therapeutic marker. Design: 117 tumors (48 malignant and 69 benign) and 6 normal salivary glands were examined for PSMA staining by immunohistochemistry using previously constructed tissue microarrays. The cases included: 27 mucoepidermoid carcinomas (MEC),17 adenoid cystic carcinomas (AdCC),2 acinic cell carcinomas (AcCC),2 mammary analogue secretory carcinomas (MASC),7 basal cell adenomas (BCA),13 Warthin tumors (WT), and 49 pleomorphic adenomas (PA). The presence or absence of PSMA staining was noted as well as distribution (cell type and localization) and intensity (score: 0 negative, 1+ weak, 2+ moderate, 3+ strong).
Results: All normal salivary gland showed weak to moderate apical PSMA staining in intercalated duct epithelium. 12/17 (71%) AdCC showed PSMA staining predominantly in ductal cells in an apical pattern and rarely in myoepithelial cells where it showed cytoplasmic staining. 1/2 (50%) AcCC showed moderate diffuse cytoplasmic staining. 5/7 (71%) BCA showed moderate to strong PSMA staining in ductal cells only. All MEC and MASC were negative for PSMA. 21/40 (53%) PA showed weak to moderate PSMA staining in ductal cells in an apical pattern and myoepithelial cells in the cytoplasm. 10/13 (77%) WT showed weak cytoplasmic staining in the oncocytic epithelium. PSMA staining was observed in the neovasculature of 29/48 (60%) malignant tumors only. 25/27 (93%) MEC and 4/17 (24%) AdCC showed PSMA staining in the neovasculature.
Of the 25 positive MEC, 9 showed weak staining and 16 moderate to strong staining. PSMA staining in AdCC was predominantly weak. Differences in PSMA expression did not correlate with grade or other clinicopathologic characteristics. Conclusions: PSMA staining is only present in the neovasculature of malignant salivary gland tumors, similar that described previously in other solid tumor types. As such, PSMA could be explored as a novel anti-angiogenic therapeutic target. Additional cases are being analyzed to explore the potential diagnostic role of PSMA in salivary gland tumors with intercalated duct differentiation. Unusual sites included base of tongue (n=2), retromolar trigone (n=2), trachea (n=1), and thyroid (n=1). Among patients with lymph node sampling, the nodal metastatic rate was ~29%. Three patients presented with distant metastases (lung, bones, thyroid). Nine patients received radio-or chemoradiotherapy. Of 64 patients with available follow-up, 13 developed recurrence. Tumors were characterized by invasive (n=75) or pushing (n=66) border, or were encapsulated (n=13). Sclerosis was noted in 81/142 and lymphoid stoma in 32/131 cases. High grade transformation (HGT; n=10) was defined by nuclear pleomorphism and necrosis. Conclusions: It appears that MASC is more common than initially thought and affects male patients slightly more commonly. Among patients whose surgical treatment included lymph node sampling, the rate of regional lymph node metastases is ~29%. The clinically aggressive cases and expanded morphologic spectrum of MASC may require a formal grading scheme and criteria for HGT-MASC. with a previous diagnosis of NOS adenocarcinoma). The median age was 46 and the male:female ratio was 8/7. 57% developed into the parotid gland and the papillary-cystic and solid pattern were the most frequent pattern (10/15). Mammoglobin and PS100 were respectively expressed (> 25% positive cells) in 12/15 and13/15 of the cases. These 2 markers were co-expressed in 12/15 cases. Three cases without ETV6 rearrangement coexpressed PS100 and mammoglobin (1ACC and 2 PLGA). On the contrary ETV6 rearrangement was found positive in a case which stayed negative for PS100 and mammoglobin. Among the 14 ETV6 FISH positive cases, 7 showed a standard ETV6 rearrangement and 8 presented a more complex anomaly including 3 with duplication of the 3' or 5' ETV6 gene , 2 with complete ETV6 gene deletion of the other allele, 2 with a 3' deletion of the ETV6 gene and 1 with a complete ETV6 deletion). Four of these 8 cases showed nerve infiltration and 3 had a pejorative outcome (2 recurrences and 1 metastatic case). We did not observed recurrence or metastasis in the cases with simple rearrangement. Conclusions: In conclusion the PS100/mammoglobin co-expression is not sufficient to affirm the diagnosis of MASC. Conclusions: Predominant intraductal pattern should be recognized in MASCs and may represent a feature of an early MASC lesion. This could be interpreted as an intracystic pattern. It is important to differentiate these lesions from the low grade cribriform cystadenocarcinoma as these lesions have overlapping histologic (basal/myoepithelial layer) and immunophenotypic features (S100, SOX10, mammaglobin positivity). Awareness of this intraductal pattern is essential to avoid a misinterpretation of cystic MASCs and FISH can be helpful in differentiating these lesions. Conclusions: Despite its known impact on prognosis, MGMT and p16 status are not associated with high tumor grade or increased lymphovascular invasion, suggesting their effect on prognosis and outcome is independent of these factors. Results: There were 5 men and 2 women ranging in ages from 17 to 65 years (avg., 41 years). The patients presented with a painless cystic mass in the region of the parotid gland (5), submandibular gland (1) and neck (1). All tumors were circumscribed measuring 1 to 4 cm in greatest diameter (mean: 2 cm). Five tumors were unilocular, while two were multilocular. The cystic spaces were predominantly lined by a single epithelial cell layer with focal areas in which the epithelium was multilayered with papillary and hobnail features. Two cases had larger intraluminal microcystic and papillary growths. The neoplastic cells were round to oval with hyperchromatic to vesicular nuclei with a centrally located nucleoli and lightly eosinophilic or vacuolated cytoplasm. Tumor cells show strong positivity for S100 protein and mammaglobin, while DOG-1 was uniformly negative. ETV6 gene rearrangement was successfully identified in 5 cases.
Conclusions:
Macrocystic MASC can present diagnostic difficulties simulating benign and other malignant salivary gland lesions. This histologic variant of MASC needs to be included in the differential diagnosis of cystic lesions in the head and neck. Identification of the characteristic cytomorphological features in conjunction with immunohistochemical reactivity and molecular analysis are key in rendering the correct diagnosis. Yan Hu, Elliot Yu, Claudia Velosa, Jessica Xu, Qiuying Shi, John Tomaszewski, Scott Doyle, Margaret Brandwein. University at Buffalo, Buffalo, NY; Allegheny Health Network, Pittsburgh, PA; University of Kentucky, Lexington, KY. Background: Pathology quantifies disease through interpretion of planar images of complex processes. We think that 3D models will enhance interpretation. Worst pattern of invasion (WPOI), a prognosticator for oral squamous cell carcinoma (OSCC) represents specific patterns at tumor advancing edge. We introduce a framework for spatial visualization of WPOI using serial sections. Design: Serial slides (20 -60) from 7 T1 OSCC were scanned at high-resolution (0.25 µ/pixel). Scale-Invariant Feature Transform aligned images to occupy the same coordinates using keypoints. Elastic image registration (bUnwarpJ, Fiji) optimized keypoint alignment. Manual annotations (5 slides/case) established training sets. A two-pass classifier was used to develop tumor masks on a pixel-wise basis, first tissue vs. background, then tumor vs. non-tumor. 156 texture-based features were extracted; features were selected for retention in modeling based on minimum redundancy and maximum relevance. A classifier was trained to produce cancer likelihood masks. To ensure a smooth model, we interpolated between the image masks. 3D Object Counter plugin created whole objects.
Three-Dimensional Histology: Spatial Envisioning of Pattern of Invasion

Results:
Fig 1, top, shows nonaggressive WPOI with finger-like pushing borders. A deep protrusion (circle) is interpreted as not separated from the main mass. This assumptions is confirmed on the 3D model (bottom).
Fig 2 (top) shows a WPOI-5 OSCC with dispersed satellites (circle). The 3D model (bottom) confirmed the lack of connection between satellite and main mass.
Conclusions:
The decision point for classifying WPOI is whether a tumor satellite is separated from the main tumor. Tangential sectioning is known to mimic separation. A series of visual context-dependent assumptions are necessary to interpretation. We present proof of concept the 3D modeling can confirm inherent assumptions necessary in interpretation of planar morphology. Background: The molecular and morphological aspects of MASC are now well described; however the frequency and the clinical outcomes are still unclear as no population-based studies of this tumour have been reported to date. Design: Retrospective chart review over the 30-year period identified 1012 major salivary gland malignancies treated at the provincial oncological center. Review by two of the authors identified 244 cases that could represent MASC. 140 cases were retrieved and included on the tissue microarray (TMA). TMA was stained with H&E, S100, mammaglobin, GATA3, keratin 5, and p63, and was probed with ETV6 break-apart FISH. All cases showing S100 and mammaglobin positivity and / or presence of ETV6 rearrangement by FISH were tested by PCR for the presence of ETV6 translocation.
Results:
The original diagnoses of the 140 cases included 93 acinic cell carcinomas, 22 adenocarcinomas NOS, 19 mucoepidermoid carcinomas, 2 mucinous adenocarcinomas, and 1 each of papillary cystadenocarcinoma, clear cell adenocarcinoma, cystadenocarcinoma, and carcinoma NOS. 31 tumours showed dual positivity for mammaglobin and S100, with 28 also showing nuclear GATA3 staining. 8 of the 31 cases showed some positivity of p63 and / or keratin 5 and none of these tumors showed ETV6 translocation by FISH or PCR. Of the remaining 23 cases, 22 showed ETV6 rearrangement by FISH and 15 by PCR.
The 22 MASC cases all occurred in the parotid gland. 14 cases occurred in men and 8 in women (M:F 1.8:1). The ages ranged from 17 to 74 years with a mean of 45 years and a bimodal age distribution with minor peak in 3 rd decade and a major peak in the 6 th decade. 16 tumours were originally diagnosed as acinic cell carcinoma, 3 as adenocarcinoma NOS, 2 as mucoepidermoid carcinoma and 1 as papillary adenocarcinoma. 15 tumours were originally graded as low grade and 7 as intermediate grade.
Mean clinical follow up was 63.6 months; mean survival follow up was 101.9 months. All tumours were treated surgically. Two patients experienced recurrences. 21 of 22 patients (95%) were disease free while one patient died of the disease 42 months after diagnosis. Conclusions: MASC is an uncommon carcinoma in the major salivary glands with a low rate of recurrence. S100 and mammaglobin positivity are sensitive and specific markers of MASC in the absence of p63 and keratin 5 staining.
LEF-1 Expression in Basaloid Tumors of the Salivary Gland
Reuben P Jacob, Shannon O'Brien, Cynthia Cohen, Momin T Siddiqui. Emory University School of Medicine, Atlanta, GA. Background: Immunohistochemistry (IHC) maybe useful in separating basal cell adenoma (BCA), pleomorphic adenoma (PA), and adenoid cystic carcinoma (ACC) in some cases. Lymphoid enhancer binding factor 1 (LEF-1) is a nuclear transcription factor that is involved in the Wnt signaling pathway and influences cellular division and migration. We evaluated its expression in surgical resections (SP) and fine needle aspiration (FNA) specimens of BCA, PA and ACC as well as benign salivary gland tissue (BSG) to determine its diagnostic utility. Design: IHC for LEF-1 was performed on 62 PA (35 SP, 27 FNA), 17 cases of BCA (11 SP, 6 FNA) and 46 ACC (35 SP, 11 FNA). Nuclear staining was graded by intensity (0-3) and percentage of positive cells. Positivity in this study was defined as 1+ intensity and greater than 5% of tumor cell positivity or intensity of 2-3+ regardless of percentage. Results: Table 1 : LEF-1 analysis in SP cases
PA ( Table 2 : LEF-1 analysis in FNA cases
PA ( Conclusions: This study identified a strong role for LEF-1 as a diagnostic marker in distinguishing basaloid tumors of the salivary gland, especially when comparing benign (PA + BCA) and malignant (ACC) lesions. LEF-1 is a useful marker for diagnosing PAs and BCAs in SP specimens and for PAs in FNA's. However with 90% of ACCs in SP and FNAs being LEF-1 negative, it can also be very helpful in excluding it as a diagnosis. LEF-1 expression was negative in all BSG. In conclusion, LEF-1 is most useful in the diagnosis of benign salivary gland basaloid tumors. Background: HPV-associated oropharyngeal squamous cell carcinoma (SCC), typically arising within tonsillar epithelium, are often described having "basaloid", "non-keratinizing" or "poorly differentiated" morphology. However, there is a wide spectrum of histological patterns, and the correlation between histological features and patient outcomes has not been well-established. The aim of this research was to identify histologic features associated with aggressive behavior of tonsillar SCC. Design: H&E slides from 129 patients with primarily resected tonsillar SCC were evaluated for histologic features, including tumor architectural pattern, degree of keratinization, host reaction, and cytological features. Medical record was reviewed for clinicopathologic features including LVI, PNI, stage, patient age, sex, risk factors and outcomes including local recurrence (LR), distant metastasis (DM) or survival (OS). Outcomes were evaluated using the Kaplan-Meier method. P values of < 0.05 were considered statistically significant. Results: HPV status was known, and positive in 91.5%. 89% of patients were male, and mean age at diagnosis was 60 yrs. (range 41-89). Mean follow-up was 34 months (range 1 to 86). All tumors arose in tonsillar tissue from base of tongue (37.2%), palatine tonsil (49.6%) or other oropharyngeal sites. Nonsmokers accounted for 48.8% and 48.8% had no history of alcohol abuse. 15% of patients were Stage I-II at diagnosis. There were 8 LRs, 9 DM and 10 deaths. As expected, lower T stage was associated with improved survival (p= 0.03), while lymph node status was not significant. Morphologic features associated with improved OS included tumors with any areas of spread along crypt epithelium (mimicking in situ carcinoma) (p= 0.03), and papillary architecture (p= 0.05). Lymphoepithelial morphology (p= 0.05), presence of frequent monster tumor nuclei (p= 0.03), and high overall nuclear pleomorphism (p= 0.0001) portended worse OS. Nuclear pleomorpism and desmoplasia were associated with DM (p<0.05), while lymphoepithelial morphology and monster nuclei were associated with LR (p<0.04 Background: Sinonasal hemangiopericytoma (HPC) is a tumor showing pericytic myoid differentiation that is unique to the sinonasal tract. CTNNB1 mutations appear to be a consistent aberration in sinonasal HPC, and nuclear expression of β-catenin has been reported. Our aim was to evaluate the frequency of β-catenin expression in sinonasal HPC and its histologic mimics in the upper aerodigestive tract. Design: Cases were retrieved from the authors' files. All tumors were located in the sinonasal tract or oral cavity, and diagnoses were based on standard and widely accepted diagnostic criteria. Immunohistochemical staining for β-catenin was performed using a mouse monoclonal antibody (BD Bioscience, #610154) at a 1:1000 dilution with antigen retrieval by citrate buffer and pressure cooker. Appropriate positive and negative controls were used throughout. Nuclear staining was recorded semiquantitatively by extent (0/negative, no staining; focal, <10% of cells; multifocal, 25%-75%; diffuse, >75%) and intensity (graded as weak, moderate, and strong). Results: Nuclear reactivity for β-catenin was found in 19/20 cases of sinonasal HPC; 17 showed moderate-to-strong multifocal or diffuse staining, and 2 had moderate focal nuclear reactivity. All solitary fibrous tumors (SFT) (10/10) showed focal-tomultifocal staining varying from weak to strong in intensity. Most cases of synovial sarcoma (9/10) showed β-catenin expression in the spindle cell component, ranging from focal-weak to strong-multifocal. No cases of myopericytoma (0/10) showed nuclear β-catenin expression.
Prognostic Significance of Histologic Features in HPV-
Conclusions: β-catenin expression is prevalent in sinonasal HPC, but is also frequent in SFT and synovial sarcoma. No expression is present in myopericytoma. Our findings indicate that β-catenin is not a useful differential diagnostic tool in the evaluation of spindle cell tumors with a prominent hemangiopericytoma-like vasculature in the sinonasal tract and oral cavity.
Characterization of Inflammatory Infiltrates and Programmed Death Ligand 1 (PD-L1) Expression in Squamous Carcinoma Precursor Lesions in Organ Transplant
Recipients D Anand Rajan Kanagasabapathy, Samir K El-Mofty. Washington University School of Medicine, St Louis, MO. Background: Perilesional inflammation plays an important role in the evolution of head and neck cutaneous squamous carcinoma (SCC). Studies have shown reduced inflammation in cutaneous SCC in organ transplant recipients (OTR). We identified two distinct SCC precursor lesions in a cohort of OTRs, bowenoid and nonbowenoid dysplasia (BD and NBD), exhibiting differential but low-level HPV β mRNA expression (in BD). Here we characterize the composition of the perilesional inflammatory infiltrate and investigate programmed cell death 1 ligand 1 (PD-L1) expression in the two types by immunohistochemistry. Design: We assembled 60 paraffin embedded tissue cores (1.5 mm) from skin biopsies of 40 organ transplant recipients (OTR) in two tissue microarrays (TMA). These included BD (n=33) and NBD (n=17) lesions and controls from adjacent skin (n=10). Immunohistochemistry for CD20, CD3, CD4, and CD8 and CD56 were performed on TMA sections using standard techniques. Perilesional infiltrating lymphocytes (PIL) and marker expression were graded on an ordinal scale from 0 to 4, representing absent-0, rare-1, scattered-2, aggregates-3 and dense bandlike-4 infiltrates. Additionally we classified marker expression on a binary scale as sparse/absent (0) or present (1). PD-L1 expression was studied using a monoclonal antibody (clone SP142, Spring Biosciences); tonsillar crypt epithelium served as positive controls. Frequency and amount of expression were compared using χ 2 and Student t-tests. Results: Inflammation was present in BD as lymphoid aggregates or a lichenoid band, compared to NBD and controls, which exhibited sparse scattered lymphoid cells. PILs were predominantly CD3+ve T-cells, and CD20+ve B-cells were sparse-to-absent in the cores including controls (p<<0.05). CD4+ve PILs were both more frequent (p=0.04), and significantly increased in number in BD compared to NBD (p=0.02). CD8-positive PILs were frequent in BD compared to NBD (p=0.02). CD56-expressing lymphocytes were not seen and PD-L1 expression was negative in both lesional types. Conclusions: Here we show a preserved CD4/CD8+ve inflammatory response in one type of precursor SCC (BD) but not in others (NBD) in OTRs. However, PD-L1 expression is negative in both types. The biologic behavior of precursor SCC associated with HPV β may be different and influenced by host inflammation. Delineation of molecular differences may eventually be used in different therapeutic methods to prevent progression in these distinct entities.
Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals a Relatively Low Overall Genomic Alteration Frequency, but Identifies Numerous Potential Opportunities for Targeted Therapies
Sungeun Kim, Kyle Fedorchak, Siraj M Ali, Julia A Elvin, Jo-Anne Vergilio, James Suh, Vincent A Miller, Philip J Stephens, Jeffrey S Ross. Albany Medical College, Albany, NY; Foundation Medicine Inc., Cambridge, MA. Background: Esthesioneuroblastoma (ENB), known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses and pursues an aggressive clinical course. We queried whether comprehensive genomic profiling (CGP) of relapsed/refractory ENB could uncover genomic alterations (GA) that could potentially lead to targeted therapies for these patients. Design: DNA was extracted from 40 microns of FFPE sections from 30 consecutive clinical cases of relapsed/refractory ENB. CGP was performed using a hybrid-capture, adaptor ligation based next generation sequencing assay to a mean coverage depth of 561X. The results were analyzed for short variant genomic alterations (GA) including base substitutions, insertions and deletions and select rearrangements as well as for copy number changes (amplifications and homozygous deletions). Clinically relevant GA (CRGA) were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials. Results: The 20 male (67%) and 10 female (33%) ENB patients had an age of 49.5 years (range 16 to 70 years). All tumors were stages III and IV at the time of CGP. The sample used for sequencing was from the primary or recurrent ENB in the head and neck or nasal cavity in 14 (47%), brain in 6 (20%), lymph node in 5 (17%), bone in 4 (13%) and liver in 1 (3%) on the ENB cases. 22 (73%) of ENB featured GA with an mean of 1.9 GA/sample. 16 (53%) ENB featured at least one CRGA with a mean of 0.73 CRGA/sample. The most frequent GA at 23% of ENB were mutations in TP53 with GA in CDKN2A, CDKN2B, CDKN2C, CTNNB1, HGF, NF1, PIK3CA, SMARCD1 and TET2 all occurring at 7% on ENB. In addition to the relatively low frequency of GA in ENB were the infrequent mutations in RB1 at 3%. Noteworthy potential targetable GA in ENB included HGF at 7% and ERBB2, KIT and PTCH1 all at 3% frequencies. CRGA impacting the MTOR pathway and potentially selecting the use of MTOR inhibitors included NF1 and PIK3CA at 7% of ENB and PTEN, TSC1/2 and RICTOR each at 3%. Conclusions: Current multi-modality non-targeted therapy for relapsed ENB is of limited clinical benefit. CGP revealed potential new therapy targets for the disease including GA in HGF, ERBB2, KIT and PTCH1. Based on these findings, further study of CGP for ENB patients appears warranted. Background: Extranodal follicular dendritic cell sarcoma(FDCS) of Head and neck (H &N) region are extremely rare. Till date, less than 80 cases are reported in literature. We hereby, report the clinico-pathological spectrum of extranodal FDCS of H&N region, reported from a single institution. Design: Eighteen cases of extranodal FDCS of H&N region were retrieved from pathology archives diagnosed over last 15-years(2001-2015) . Clinicoradiological information was obtained from patient's charts. Histopathological and immunohistochemical (IHC) features were reviewed. Risk stratification into low risk and high risk malignant potential was done based on following parameters; growth pattern, cellular atypia, necrosis(-/+) and mitotic count/10hpf(<5 or >5) and tumour size (<5 or >5cms). Results: The study group was formed by 14 males and 4 females, between 17-79 years of age (median, 50 years). Common clinical symptoms were intra-oral and nasal discomfort, swelling and odynophagia. Imaging revealed lobulated soft-tissue masses, ranging in size from 1-7 cms (median, 4.7cm). Primary site were tonsil (n=8),pharyngeal region(n=5) and larynx(n=2). Parotid, scalp and thyroid had one case each. The tumor was characterized by spindled to ovoid cells arranged in varying growth patterns i.e. storiform, fascicular, whorled and solid. Sprinkling of lymphocytes within tumour was common finding. A wide IHC panel for epithelial, melanoma and lymphoma markers was negative. Variable expression for FDC markers was seen i.e.CD23(18/18),CD21(13/17) and CD35(5/9)]. Risk stratification based on histology findings was possible in 16 cases and their correlation with clinical outcomes was showed in Treatment modalities were only surgery in 5, surgery plus adjuvant chemo-radiotherapy in 9 and only chemo-radiotherapy in 4 cases. Median follow-up was 26 months(range 4-120 months) and 9 patients were alive with disease. Local recurrence, lymph node and distant metastasis were noted in 4, 7 and 2 patients respectively. Late recurrence after 8 and 10 year was noted in 2 cases. Recurrent tumours were high grade on histomorphology.
Conclusions: Extranodal FDCS of the H&N region is an uncommon tumour and high index of suspicion with wide IHC panel is required for diagnosis. Histopathological risk stratification may determine the prognosis of the tumour. Its apparently lytic nature may lead to the clinical impression of osteomyelitis or malignancy. Although characteristic imaging features have been reported, APSB remains poorly recognized by general radiologists. In addition, APSB has not been previously described in the pathology literature. We have recently encountered several consultation cases in which biopsy was performed for a supposedly aggressive skull base process. Because of bland histologic features, submitted images were reviewed with our neuroradiologists, who interpreted the findings as those of APSB. We describe the pathologic features of 5 such cases. Design: Consultation files were reviewed to identify possible cases of APSB. Accepted cases had benign histology without another specific diagnosis, and review of images by one of our experienced neuroradiologists to confirm the interpretation. Results: There were 3 males and 2 females ranging in age from 17 -54 years (mean, 41). A skull base lesion was detected at the time of imaging for unrelated symptoms. The sphenoid bone was involved in 3 cases, the clivus in 1, and both in 1. Submitting pathologists considered the diagnoses of infection, inflammatory process, storage disease, fibrous dysplasia, histiocytosis, mastocytosis, granular cell tumor, xanthoma, and lipoma. Biopsy specimens showed fragments of sclerotic bone (3 cases) admixed with mature fat (5), foamy histiocytes (4), irregular strands of fibrosis (4), mild chronic inflammation (5), and coarse calcifications (4). These features correlated with imaging findings of sclerotic margins, internal fat and soft tissue densities, and curvilinear calcifications. Special stains were limited due to small specimen size. Histiocytes were positive for CD163 or CD68 (3/3 cases) and negative for S-100 (4/4). Keratin immunostain was negative in all cases (3/3), as were special stains for microorganisms (2/2). Conclusions: APSB is a developmental variant that may be found incidentally during investigation of another condition. Imaging features may appear alarming to those unaware of this phenomenon. The head and neck pathologist should be familiar with its characteristic histology, in order to avoid excessive special stains or further workup including potential rebiopsy of this critical anatomic site. The diagnosis of APSB emphasizes the importance of radiologic-pathologic correlation in the evaluation of skull base lesions. There are several molecular pathways involved in the pathogenesis of NPC. JAK2 is one of the four members of the Janus kinase (JAK) family, and its mutation is an important oncogenic driver in myeloproliferative neoplasms and certain hematopoietic malignancies. By using public domain datasets and our well-characterized cohort, we intended to analyze the association of JAK2 expression in NPC. Design: Two datasets from GEO (GSE12452 and GSE34573) were used to analyze the significance of JAK2 transcript expression between tumor and non-tumor specimen. JAK2 immunostain was performed on 124 cases of NPC and interpreted using H-score. The result was then correlated with clinicopathological features, disease-specific survival (DSS), distal metastasis-free survival (DMeFS), and local recurrence-free survival (LRFS). Twenty NPC cases with JAK2 overexpression were also submitted for JAK2 exon 12 and JAK2 V617F mutation analyses using PCR followed by direct sequencing. oncocytic and mucinous variants were seen. The tumours showed androgen receptor (70%), HER2 amplification (30%) and HRAS, AKT1, PIK3CA and NRAS mutations (22%; cumulative). The five-year disease free survival was 36%. Conclusions: SDCa demonstrate a wide histopathologic spectrum. Treatment strategies need to take androgen receptor, HER2 amplification and PIK3CA mutation into account. The goal of this study is to determine the incidence of these tumors in a large, diverse metropolitan population. Design: All available SGCA specimens diagnosed at our institution between 1994 and 2014 were retrieved from the pathology archives. H&E slides were reviewed and reclassified, taking into account recently described entities, including cribriform adenocarcinoma of minor salivary glands (CAMSG), mammary analogue secretory carcinoma (MASC), clear cell carcinoma (CCCA) and sinonasal adenoid cystic like carcinoma. Cases with equivocal diagnoses were grouped in a separate category for further workup by immunohistochemical and/or molecular studies. Results: Of 596 patients diagnosed with SGCA, 495 (83%) had slides available for review. Initial diagnoses were confirmed in 322 (65%) of cases, changed in 97 (20%) and required further diagnostic workup in 76 (15%). 8 cases were reclassified as benign, and 15 as not of salivary gland origin. After reclassification, SGCA diagnoses included: 18/472 (4%) MASC, 18 (4%) CCCA, 6 (1%) CAMSG and 1 sinonasal adenoid cystic like carcinoma. Mucoepidermoid carcinoma was the most common diagnosis (n=132, 28%), followed by adenoid cystic carcinoma (n=74, 16%), SGCA NOS (n=36, 8%, including 13 carcinoma ex-pleomorphic adenoma), acinic cell carcinoma (n=29, 6%), polymorphous low grade adenocarcinoma (n=24, 5%) high grade salivary ductal carcinoma (n=23, 5%), myoepithelial carcinoma (n=13, 3%), epithelial-myoepithelial carcinoma (n=12, 3%), and basal cell adenocarcinoma (n=4, 1%), with rare entities including neuroendocrine carcinoma, and cases requiring additional workup accounting for the remainder of cases.
Conclusions:
Recently described entities accounted for 9% of SGCA in a preliminary morphologic assessment of salivary gland carcinomas. Further immunohistochemical, molecular, and clinicopathologic studies are pending to confirm diagnoses in equivocal cases and determine the significance of reclassification on tumor prognosis.
Ameloblastoma: Twenty Five Year Experience at a Single Institution
Tatyana Milman, Wei Pan, Virginia LiVolsi. Perelman School of Medicine, Philadelphia, PA. Background: Ameloblastoma is a rare, locally aggressive odontogenic neoplasm, accounting for 1% of head and neck tumors. Recent literature suggests that the surgical approach and histologic growth patterns are the most important prognostic determinants in ameloblastoma. The aim of this study was to compare the clinical presentation, surgical management, and outcomes of patients with ameloblastoma, spanning the course of 2 decades at a single institution, with the data reported in the literature. Design: Following the IRB approval, the institution's database was searched for all patients with pathologically confirmed ameloblastoma, diagnosed between 1990 and 2015. The data collected included sex, age, tumor location, management, recurrence, time to recurrence, disease-related mortality, length of follow-up, histologic pattern, and clearance of surgical margins. The potential risk factors of recurrence were evaluated using log-rank test and proportional hazard model for calculating hazard ratio and its 95% confidence intervals (95% CI). The statistical analyses were performed in SAS V9.4 (SAS Institute Inc, Cary, NC) and two-sided p<0.05 was considered to be statistically significant. Results: Review of the database yielded 54 patients with pathologically-confirmed ameloblastoma and a sufficient follow-up. There was male predominance (39 males, 15 females). Ameloblastoma was diagnosed at a median age of 57.5 years (range 13-88). Nineteen tumors were localized to the maxilla (35%) and the remainder involved the mandible. Radical resection (total or radical maxillectomy or mandibulectomy) was performed in 33 (61%) of the patients, while the remainder were managed with limited surgery. The average length of follow-up was 6.4 years (range 0.1 -30). Recurrence was noted in 13 (24%) patients. Surgical approach was strongly associated with the risk of recurrence (RR=11.1, p = 0.002). There was a trend toward higher recurrence rate in the group with pathologically documented positive margins, but it reached borderline statistical significance (42.1% vs, 14.8%, p=0.054). There was no significant association between the recurrence and the patient age, sex, tumor location, or histologic pattern. Malignant transformation into ameloblastic carcinoma was identified in one follicular ameloblastoma. None of the patients succumbed to their disease. Conclusions: Our study confirms the recent data regarding the importance of complete surgical resection in management of ameloblastoma. Surgical approach appears to be the strongest predictor of tumor clearance. The most common response at PT was fibrosis, followed by inflammation in contrast to that in LNM being keratin flakes and calcification TRG was significantly associated with TG in PT (p 0.000) and PVT in LNM (p 0.003). In addition, MTRG, but not TRG, was seen significantly associated with N stage (p 0.043) and DFS (p 0.037). No significant association of OS was seen with TRG or MTRG. On multivariate analysis, OS was significantly associated with PVT in LNM (p 0.015), in addition to time tested parameters: TG in PT (p 0.000) and N stage (p 0.001).
Prognostic Significance of Histological Tumor Regression at Primary Site and Nodal Metastases in Patients with
Conclusions: Modified TRG in PT and PVT in LNM prove to have prognostic significance and warrant inclusion of these parameters while reporting post NACT specimens. This will help us to identify and study biology subset of tumors not responding to therapy and individualize the NACT regimen.
Investigation of High Risk HPV E6/E7 mRNA Transcriptional Activity by In Situ Hybridization in Sino-Nasal Inverted Papilloma with Associated Dysplasia and Malignant Transformation Shobha Parajuli, Rashmi Tondon, Amy Ziober, Kathleen Montone, Kumarasen Cooper.
Hospital of the University of Pennsylvania, Philadelphia, PA. Background: Schneiderian inverted papilloma comprises 0.5% nasal tumors and affects males in 6 th decade with a recurrence rate of 12.8-34%. Malignant transformation is a poorly understood complication seen in 5-15%. HPV 6/11 has been implicated in benign papilloma while oncogenic types 16/18 are associated with malignant transformation. Previous HPV detection rates of 37.8-100% depended on histological type, sample size and methodology. A recent study examining HPV E6/E7 mRNA transcripts in inverted papilloma suggested a higher sensitivity than PCR. (Stoddard, 2105) Design: We evaluate the high-risk HPV E6/E7 mRNA expression in inverted papilloma with malignant transformation. We performed a retrospective study of 19 patients with inverted papilloma and dysplasia with or without malignant progression from 2005 to 2015 at Hospital of the University of Pennsylvania. After review, FFPE specimens were evaluated for HR HPV E6/E7 mRNA transcription using chromogenic in situ hybridization. Results: Of 19 cases of inverted papilloma with dysplasia, 14 cases (70%) demonstrated malignant transformation into invasive squamous cell carcinoma. 70% were male, with average age of 67 years (range 53-90 years). RNAscope detected HPV mRNA transcripts in 10 patients (71%) with malignant transformation and 4 patients (80%) without malignant transformation. Invasion in 2 cases of inverted papilloma was cut through. High level of expression of mRNA transcripts was noted in 5 cases (36%) with malignant transformation and 3 cases (60%) without malignant transformation. Low level of expression of mRNA transcripts was noted in 5 cases (36%) with malignant transformation and 1 case (20%) without malignant transformation. Benign inverted papilloma was present in 13 cases with high level of expression in 3 cases (23%) and low level of expression in 8 cases (61%).
Conclusions:
This study demonstrates a high prevalence of HR HPV in sino-nasal inverted papilloma with dysplasia, and an equally strong correlation with malignant transformation. These findings are highly suggestive of an etiological role for HPV in the transformation of IP to dysplasia to squamous cell carcinoma. Background: Polymorphous low-grade adenocarcinomas (PLGA) can have a wide variety of histologic architectural patterns, hence the name "polymorphous." This leads to difficulties in distinguishing this entity from many other salivary gland neoplasms, in particular cellular pleomorphic adenomas and adenoid cystic carcinomas. Accurate diagnosis is essential since PLGA and adenoid cystic carcinomas are malignant while pleomorphic adenomas are benign. Thus far, immunohistochemical stains haven't been helpful. However, recently Rooper et al. reported an immunophenotype of p63+/p40-in 100% of PLGA, and p63+/p40+ for 90% of adenoid cystic carcinoma. Design: We reviewed H&E slides from 16 PLGA, 9 cellular pleomorphic adenomas, and 10 adenoid cystic carcinoma within the department archives. The diagnosis on H&E was confirmed by the investigators. IHC for p40, p63, and Ki-67 was performed for each case. The IHC stain results were independently reviewed by the two faculty pathologists. For p40 and p63, positivity or negativity was reported along with whether staining pattern was "diffuse" or "patchy." The Ki-67 mitotic index was estimated by only one faculty Pathologist. Results: Of the PLGAs, 13/16 had the p63+/p40-immunophenotype while 8/10 adenoid cystic carcinoma had the p63+/p40+ immunophenotype. The staining pattern for cellular pleomorphic adenoma was variable with 4 cases displaying the p63+/p40+ immunophenotype and the remaining 5 cases displaying the p63-/p40-immunophenotype. Of the 13 PLGAs with the p63+/p40-immunophenotype, 5 cases had a p63 which was positive only in a patchy distribution. The average Ki-67 mitotic index was 4.93 ± 2.49 for PLGAs, 5.11 ± 2.14 for cellular pleomorphic adenoma, and 15.20 ± 10.67 for adenoid cystic carcinoma. Conclusions: A p63+/p40-immunophenotype is specific for the diagnosis of PLGA as 13/14 cases with this phenotype were PLGAs. However, these immunostains may not be reliable when making the diagnosis on small biopsy since the pattern of p63 staining was considered "patchy" in 5 of 13 of the PLGAs with the p63+/p40-immunophenotype.
Overall, both p63 and p40 has value when these entities are in the differential diagnosis. The Ki-67 mitotic index was noticeably higher in the adenoid cystic carcinomas when compared to cellular pleomorphic adenomas and PLGAs. However, there was no significant statistical difference, likely due to the small sample size. Asawari Patil, Tanvee Kulkarni, Ashwini Natu, Munita Bal, Rajiv Kumar, Swapnil Rane, Shubhada Kane. Tata Memorial Centre, Mumbai, Maharashtra, India. Background: Scheiderian papilloma (SP) are uncommon benign epithelial neoplasms of sinonasal tract. Malignant transformation in SP (CA-ex-SP) is exceedingly rare (11%). Very few series in literature provide comprehensive review of Ca-ex-SP. This study describes clinico-pathological profile of 27 cases of sinonasal Ca-ex-SP diagnosed at a tertiary cancer care centre. Design: Cases of sinonasal Ca-ex-SP or sinonasal carcinoma with prior history of SP, diagnosed at our institute during 2009-2015, were retrieved from pathology archives. Only those cases were included in the study which showed at least focal area of residual SP along with carcinoma or SP in prior biopsy. Histopathological parameters reviewed include: Tumor type, tumor grade, type of SP and dysplasia in SP. Clinical details and radiological findings were obtained from electronic medical records. Results: 27 cases of sinonasal Ca-ex-SP were identified with male to female ratio being 1.7:1.0 and age ranging from 35 to 70 years (Mean: 51). Ten cases showed tumor involving multiple anatomic sites. The commonest site involved was maxillary sinus (21 cases) with extension to nasal cavity, followed by ethmoid sinus (6 cases) extending to frontal sinus in 2 cases and sphenoid sinus in 1 case. Majority of them were squamous cell carcinoma (25 cases, including: 14 poorly differentiated, 8 moderately differentiated, 2 well differentiated, 1 transitional type), others being undifferentiated carcinoma (1 case) and adenosquamous carcinoma (1 case). Synchronous tumors were common (24 cases), while three were metachronous with prior history of SP. Invasive focus was differentiated from papilloma by presence of one or more of following features: loss of basement membrane, cellular pleomorphism, paradoxical maturation, atypical mitoses, stromal response. The commonest morphology of residual papilloma was inverted type (in 25 cases), followed by oncocytic type (1 case, associated with adenosquamous carcinoma) and mixed inverted-oncocytic type (1 case). Dysplasia ranging from mild to severe was seen in residual SP with three cases showing carcinoma-in-situ. Two cases showed scanty focus of invasive carcinoma associated with SP showing severe dysplasia in one case and carcinoma in situ in the other. Conclusions: This is largest series of sinonasal Ca-ex-SP, an uncommon tumor. These tumors are known to have better clinical outcome. Presence of dysplasia in SP associated with carcinoma is described in literature and is also seen in our series. A thorough examination of specimen of SP with dysplasia is needed to look for presence of invasive carcinoma. 
Sinonasal Carcinoma Arising in Schneiderian Papilloma: Clinicopathological Review of 27 Cases
HPV Prevalence in HIV Patients with Head and Neck Squamous Cell Carcinoma
Background:
The implication of HPV in head and neck squamous cell carcinoma (HNSCC) is well established, especially in oropharyngeal SCC. HIV patients have a higher risk of persistent HPV infection. We investigated the role of HPV in HNSCC carcinogenesis in HIV population. Design: We conducted a retrospective monocentric study. We studied HIV patients who presented with HNSCC between 1994 and 2014. For each patient, tumor characteristics, HIV disease and survival information were collected. Tumor HPV testing was performed using p16 immunohistochemistry, in situ hybridation and PCR. We assessed the percentage of HPV in this population of HIV patients with HNSCC and compared HIV disease characteristics based on HPV status. Results: Forty seven patients were included : 11 women/36 men, the median age was 50 years. Tumor HPV testing was performed in 40 patients. Tumors were located in oropharynx (32%), oral cavity (32%), larynx (21%) and hypopharynx (11%). At the time of diagnosis, median CD4 level was 385/mm 3 , 31% of the patients were stage CDC C. The percentage of HPV linked to HNSCC for all locations in HIV patients was 30% (n=12). HPV16 accounted for 50% of all HPV genotypes. HPV positive status was associated with a stage CDC 3 (p=0,026), but not with CD4 level at time of diagnosis (p=0,414). HPV negative tumor was associated with poorer 5-year overall survival (HR=15,2 ; IC95% 2,5-92,5 ; p=0,0031). Conclusions: HPV plays a critical role in HNSCC development in HIV population. HIV immunodeficiency may increase HPV persistence and progression of HNSCC.
MYC and MYB Are Coexpressed in Adenoid Cystic Carcinoma
Marc Pusztaszeri, Patrizia Bordignon, Thomas McKee, William C Faquin. Geneva University Hospitals, Geneva, Switzerland; Massachusetts General Hospital, Boston, MA. Background: A specific translocation t(6;9) involving MYB and NFIB genes has been identified in adenoid cystic carcinoma (AdCC) where it contributes to MYB overexpression. MYB targets many genes, including c-KIT, BCL2 and MYC, involved in cell cycle control, transcriptional regulation, and apoptosis. C-KIT, BCL2, and MYC have been shown to be overexpressed in AdCC, and recently a potential role of MYC in AdCC dedifferentiation has been suggested. This is the first systematic study to investigate the combined expression of MYB and MYC protein expression in a series of AdCC.
Design:
We assessed the expression of MYB and MYC in AdCC (n=20) and in a control group of pleomorphic adenomas (PAs; n=20) using immunohistochemistry on formalin-fixed paraffin embedded tissue from surgical resection specimens. The nuclear expression of MYB and MYC was assessed semi-quantitatively using the Allred scoring system (0 to 8). Results: MYB and MYC were both variably and heterogeneously expressed in AdCC with a mean Allred score of 6.25 (range: 2-8) and 5.7 (range: 4-8), respectively. The expression levels of MYB and MYC were significantly higher in AdCC than in PAs where the mean Allred score was 2.45 (range: 0-4) for MYB (p=0.0001) and 2.75 (range: 0-6) for MYC (p=0.0001). Using a cut-off score ≥6, the sensitivity and specificity to distinguish AdCC from PA were 60% and 100% using MYB, and 50% and 95% using MYC. Focal cytoplasmic staining with MYC was also present in a minor subset of PAs but not in AdCC.
Conclusions:
The expression of MYC correlates with the expression of MYB in AdCC, and is significantly higher than in PA. This suggests that MYC is activated in MYB positive AdCC. Large clinico-pathological studies should investigate the prognostic and predictive values of MYC and MYB in AdCC.
Myb and Androgen Receptor Expression in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma
Sydney Rooney, Brennan Tesdahl, Robert Robinson. University of Iowa, Iowa City, IA. Background: Molecular markers and hormone receptor expression have been suggested to be of value in the diagnosis as well as treatment of certain salivary gland neoplasms. Basal cell adenoma and basal cell adenocarcinoma represent uncommon basaloid salivary gland neoplasms, appearing morphologically very similar to one another. Besides basal cell adenoma and adenocarcinomas, other salivary gland neoplasms are also composed of basaloid cells, sometimes causing significant difficulty in the histologic separation from these other neoplasms. Recently, myb expression has been suggested as a means of supporting a diagnosis of adenoid cystic carcinoma, which can be a mimic of basal cell adenoma and basal cell adenocarcinoma, particularly in small or limited samples. Using tissue microarrays, we studied a group of basal cell adenomas and basal cell adenocarcinomas for expression of myb and androgen receptor. Design: We have previously reviewed the pathologic features of 69 neoplasms diagnosed as basal cell adenoma or basal cell adenocarcinoma gathered from our institution. From these tumors we constructed tissue microarrays using 30 basal cell adenomas and 17 basal cell adenocarcinomas with each tumor replicated in triplicate. The arrays were then stained with antibodies to myb and androgen-receptor. Staining was assessed for presence or absence and intensity within the tumor. Nuclear staining was evaluated for both tumors and a minimum of 10% staining in the averaged tumor cores was considered positive. Intensity of staining was graded on a 1-3 (weak to strong) basis. Results: For myb, staining was almost always 2 or 3+ intensity as was androgen receptor in both the basal cell adenomas and basal cell adenocarcinomas. Basal cell adenomas expressed myb in 17/30 (57%) of cases while basal cell adenocarcinomas expressed myb in 9/17 (53%) of cases. No correlation of myb expression to clinical outcome or tumor morphologic characteristics was found with either the basal cell adenomas or adenocarcinomas. Androgen receptor expression was seen in only 1/30 (3%) of basal cell adenomas and 3/17 (18%) of basal cell adenocarcinomas and no correlation to clinical outcome or morphology was noted.
Conclusions:
The findings suggest that anti-androgen receptor agents would not be effective in treating basal cell adenocarcinomas. Myb expression does not help separate basal cell adenomas from basal cell adenocarcinomas nor does it appear likely that it could separate either of them from adenoid cystic carcinoma. Background: Biphenotypic sinonasal sarcoma (BSNS) is a recently recognized lowgrade sarcoma exhibiting both neural and myogenic differentiation. This unique dual phenotype stems from recurrent rearrangements in PAX3, a transcription factor that promotes commitment to either lineage. Among other mechanisms, PAX3 functions through activation of the Wnt-B-catenin pathway. While identification of PAX3 rearrangements by FISH can confirm a BSNS diagnosis, this assay is not widely available. This study evaluates whether an expanded immunohistochemical panel can facilitate differentiation of BSNS from mimickers including cellular schwannoma, malignant peripheral nerve sheath tumor (MPNST), and leiomyosarcoma. Design: Nine cases of BSNS were identified from the surgical pathology archives of two academic medical centers. In 6 cases, the diagnosis was confirmed by FISH using custom probes for PAX3; in 3 cases FISH failed but histologic and immunophenotypic findings were diagnostic for BSNS. Immunohistochemistry (IHC) for S100, calponin, SMA, B-catenin, SOX10, myogenin, desmin and factor XIIIa was performed on whole slide sections. Results: All 9 BSNS (100%) were at least focally positive for S100 as well as calponin and/or SMA. In addition, 8/9 BSNS (89%) expressed nuclear B-catenin, 6/8 (75%) were positive for factor XIIIa, 4/9 (44%) expressed desmin, and 3/8 (37.5%) were positive for myogenin. All 9 tumors were negative for SOX10.
Nuclear B-catenin Expression Provides a Consistent
Conclusions:
Most cases of BSNS exhibit nuclear B-catenin immunoreactivity, consistent with Wnt-B-catenin activation resulting from their characteristic PAX3 rearrangements. In light of previous studies showing that cellular schwannomas, MPNSTs and leimoysarcomas do not express B-catenin in a nuclear distribution, an immunohistochemical profile that includes B-catenin could help separate BSNS from these mimickers and establish the diagnosis without the need for gene rearrangement studies. Background: The need to establish the HPV status of oropharyngeal squamous cell carcinomas (OPSCCs) is important, but the ability to perform accurate HPV testing has been jeopardized by the recent withdrawal from the market of a popular first-generation DNA in-situ hybridization (DISH) probe. A second-generation HPV DISH platform has since been introduced but has not been rigorously evaluated against other highly sensitive and specific assays such as RNA-in situ hybridization (RISH). Design: The second-generation Patho-Gene HPV Type 16/18/31/33/51 DISH (Enzo Life Sciences, Lausen, Switzerland) was performed on 83 whole-slide sections of OPSCCs that had previously been evaluated with p16 immunochemistry (MTM Laboratories, Heidelberg, Germany) and RNAscope HPV-HR18 RISH (Advanced Cell Diagnostics, Hayward, CA). All slides were independently scored by 3 reviewers. Results: Patho-Gene HPV DISH was positive in only 17 out of 59 (28.8%) cases that were positive for p16 and HPV RISH. It was negative in all 5 cases (0%) that were p16 positive but HPV RISH negative. It also was negative in all 19 cases (0%) that that were p16 negative and HPV RISH negative. Reviewers achieved only moderate inter-observer agreement when evaluating Patho-Gene DISH (kappa = 0.704), while HPV RISH facilitated almost perfect agreement (kappa = 0.939).
This study demonstrates that a second-generation HPV DISH probe has inferior performance for HPV detection compared to HPV RISH. The sensitivity of Patho-Gene HPV was just 28.8% compared to a gold standard of RISH positivity. Moreover, Patho-Gene HPV showed considerably poorer inter-observer agreement than RISH. HPV RISH remains a preferable alternative to second-generation HPV DISH for HPV testing in OPSCC.
Expression of an Androgen Receptor Splice Variant in Salivary Duct Carcinoma: An Instrument of Resistance?
Dipti Sajed, Chin-Lee Wu, Vania Nose, Vikram Deshpande. Massachusetts General Hospital, Boston, MA. Background: Salivary duct carcinoma (SDC) is an aggressive salivary gland tumor which presents at an advanced stage, often with nodal metastases, and has a high recurrence rate. Despite aggressive management with resection, lymph node dissection, and chemoradiation, SDC carries a poor prognosis. Alternative therapeutic efforts exploiting androgen receptor (AR) expression in these tumors in the form of androgen deprivation therapy (ADT) have not demonstrated unequivocal clinical benefit. Recent revelations in the field of prostate cancer have highlighted a strong association of the expression of a ligand-independent, constitutively active AR splice variant -ARV7 -with resistance to ADT. Similarly, we hypothesize that the expression of ARV7 in SDC may in part account for resistance to ADT observed in preliminary studies. Design: In situ hybridization (ISH; QuantiGeneⓇ ViewRNA, Affymetrix) using AR and ARV7 RNA probes was performed on 12 FFPE tissue samples from patients with SDC. Scoring as follows: 3 -diffuse signal at 4x; 2 -diffuse signal at 10x; 1 -diffuse or focal signal at 20x; 0 -equivalent to background signal. AR and Her2 IHC were reviewed. Results: Age range was 50-83 (mean = 65) years, with 9 male and 3 female pts. All cases were of conventional apocrine histology with the parotid as the 1 o site (two exceptions: 1 buccal, 1 unknown). All but 3 had nodal metastases and 3 arose in the setting of carcinoma ex pleomorphic adenoma. All SDCs were diffusely positive for AR via IHC. IHC and ISH scoring as follows: A strong ISH score (3+/2+) correlated with AR positivity by IHC. There was no association between AR ISH and ARV7 ISH nor between ARV7 ISH and Her2 IHC. Conclusions: Our results indicate that AR ISH correlates with AR IHC in SDC, matching previous reports of high AR expression in the vast majority of SDC cases. Importantly, this is the first demonstration of mRNA expression of an AR splice variant that is associated with resistance to ADT in a large subset of SDCs (58%). The significance of the expression of a ligand-independent, constitutively active AR splice variant in SDC is at least twofold. One, clinical trials evaluating the efficacy of ADT in SDC should take into account ARV7 expression status to avoid masking any benefit of ADT. Two, a low expression of ARV7 might contribute to resistance, a consequence of the expansion of ARV7-positive clones. KIT (ex. 9, 11, 13, 14, 17, 18) , NRAS (ex. 2,3), and TERT promoter region (including the position of C228T and C250T mutations) were amplified by PCR. The amplicons were submitted to direct sequencing in both directions by using Big Dye Terminator kit and analyzed in the ABI 3730 automatic sequencer.
BRAF, KIT, NRAS and TERT Mutation Analysis in Head and
Results:
The Female/male ratio of patients was 18/14 with a mean age of 62.1 (28-87). Follow-up period ranged from 5 to 142 months, with a median of 16.5. Twenty four (75%) patients died from melanoma related reasons. Overall 18.75% (6/32) of cases harbored one of BRAF (1/6), KIT (1/6), NRAS (1/6) and TERT (3/6) mutations. Aforementioned mutations were observed to be mutually exclusive. Conclusions: Our results show that BRAF, KIT, NRAS and TERT mutations are rarely present in HNMMs and TERT mutation is the most frequently encountered. One other striking finding is the absence of any mutation in oral mucosa or nasopharynx. We think that our study will contribute to the literature that has limited data about molecular alterations in HNMMs. Conclusions: PD-L1 expression is frequent in OSCC, particularly in women. An inflammatory phenotype may be a surrogate marker of PD-L1 expression, particularly in small biopsies, as PD-L1 expression can be heterogeneous. Tumor Size (cm) 1.1 to 7.5 0.7 to 2.5 1.5 to 3.8
Programmed Cell Death-Ligand 1 (PD-L1) Expression in Oral Cavity
Coexisting conventional SCC > 5% 2 4 4
CC and VC predominated in oral cavity, while PEC was more frequent in larynx (5/6). All tumors were grossly exophytic, but had distinctive growth patterns. CC were defined by an endophytic growth of complex arborizing keratinizing crypts and microcysts with a corrugated parakeratotic lining. VC showed a 'church-spire' pattern of parakeratosis and bulbous broad pushing rete; PEC were predominantly exophytic, but 4/6 showed invasive components with angulated nests similar to conventional SCC (median 35%). Both CC (2/6), and VC (4/5) also showed conventional components (median 35% & 25%, respectively). Pure CC and VC components were devoid of atypia, but PEC consistently showed mild to moderate atypia even in papillary/exophytic areas. Lymphoplasmacytic infiltrates were common in CC (4/6) and VC (3/5), but not PEC. All CC also showed intraepithelial neutrophils. All variants were locally aggressive, but only one PEC with a prominent conventional SCC component (40%) showed nodal metastasis. Conclusions: CC, VC and PEC are rare locally aggressive variants of SCC delineated from one another by their growth patterns. CC and VC in pure form are truly well differentiated tumors with an inflammatory milieu, though coexisting conventional SCC is actually fairly common. PEC on the other hand have cytonuclear atypia that is similar to conventional well to moderately differentiated SCC; any perceived indolence is likely attributable to the architecture. A prominent conventional component abrogates any protective effect of this architecture as demonstrated by one case with nodal disease. Background: PNI is an established adverse risk feature in head and neck squamous cell carcinoma, and an indication for adjuvant therapies based on the National Comprehensive Cancer Network guideline. The study aims to clarify the prognostic significance of PNI in OTSCC, as it may potentially influence decision for adjuvant therapy. Design: A meticulous clinico-pathologic analysis was performed in a cohort of 381 patients with oral tongue SCC operated and followed at a tertiary cancer center between 2000 and 2012 with a median follow-up of 40 months. Results: PNI was identified in 105 patients (27.6%). The median number of PNI foci was 3 (range 1 -52). The presence of PNI had a significant association with larger tumor size, increased tumor thickness, higher tumor grade, invasion of skeletal muscle and bone, pattern of invasion, lymphovascular invasion, margin status, and lymph node positivity (Chi square test, p < 0.05), but not with lymphoid interface host response (p = 0.49). Number of PNI foci, circumference of the perineural invasion and the form of invasion (perineural or intraneural) were significantly associated with presence of cervical lymph node metastasis (Fisher's Exact Test, p < 0.05). PNI is an independent predictor for adverse clinical outcome with shortened overall survival (OS, hazard ratio HR= 2.82, p < 0.001), and disease specific survival (DSS, HR = 2.50, p = 0.003). PNI correlated with shorter locoregional/distant recurrence free survival (RFS) on univariate analysis only. Patients with extensive PNI, defined as 5 foci or more per tumor, had significantly shortened OS, DSS and distant RFS than those with focal PNI on univariate analysis. Additionally, PNI density, defined as number of PNI foci per tumor section, greater than 1.167 was an independent adverse pathological feature for predicting reduced DSS (HR = 2.61, p = 0.015) when adjusting for tumor size. Conclusions: PNI is an independent pathological predictor for adverse clinical outcome in OTSCC. In addition, stratification of the extent of PNI into foci per section seems to provide additional prognostic values. Bin Xu, Lu Wang, Laetitia Borsu, Nora Katabi, Ian Ganly, Snjezana Dogan. Memorial Sloan-Kettering Cancer Center, New York, NY. Background: High-risk human papillomavirus (HR-HPV) has been identified as a putative oncogenic driver in a significant proportion of head and neck squamous cell carcinoma (HNSCC), primarily in those arising in oropharynx. The frequency of HR-HPV in primary squamous cell carcinomas of the parotid gland (ParSCC) is unknown.
High Risk Human Papillomavirus in Primary Squamous Cell Carcinoma of the Parotid Gland
In the current study, we aimed to examine ParSCC for the presence of HR-HPV and associated molecular alterations. Design: Eight cases of ParSCC were retrieved from our pathology archives and were diagnosed over the period of 13 years. A diagnosis of ParSCC is rendered after a detailed clinicopathologic review to exclude a possibility of metastasis and/or extension from another primary site, such as skin and oropharynx. HR-HPV status was determined based on immunohistochemistry (IHC) for p16 protein expression and by chromogenic in situ hybridization (CISH) for HR-HPV. Presence of a diffuse and strong nuclear and cytoplasmic p16 immunostain in at least 70% of the tumor cells and presence of nuclear dot-like signal indicative of integrated HR-HPV were both required to consider a case HR-HPV-positive. In addition, all cases were genotyped by multiplexed mass spectrometry assay interrogating 91 hotspot mutations in 8 cancer-related genes (EGFR, KRAS, NRAS, BRAF, PIK3CA, AKT1, MEK1 and ERBB2) , and studied by IHC for PTEN protein expression. All except 2 cases (which showed retained PTEN protein by IHC) were examined for PTEN gene copy number alteration (CNA) by fluorescence in situ hybridization (FISH).
Results: Three of 8 cases (3/8; 37.5%) were positive for presence of HR-HPV by CISH and p16 IHC. One of three (1/3; 33%) HR-HPV-positive cases harbored PTEN hemizygous deletion, and one (1/3; 33%) HR-HPV-positive case harbored PIK3CA E545K somatic mutation.
No alteration of PTEN-PI3K pathway was detected in HR-HPV-negative tumors. Over a median follow-up period of 66.2 months, only the patient with HR-HPV-positive PIK3CA-mutated tumor died of his disease, while the remaining 7 patients were disease free. Conclusions: Given the established etiologic role of HR-HPV in other HNSCC, it is likely that HR-HPV represents an oncogenic driver in the pathogenesis of more than one third of ParSCC. Presence of HR-HPV in ParSCC may be coupled with alterations in PTEN-PI3K pathway. HR-HPV and molecular characterization of a larger number of ParSCC is needed to determine the clinical significance of these findings. Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in America. Lymph node (LN) metastasis is one of the main prognosticators of survival. Resistance to anoikis, a type of apoptosis induced by loss of cell-matrix contact, is a prerequisite for their metastatic spread. MUC4 is a membranebound mucin expressed in several normal tissues, and its expression is elevated in malignancies. However, the role of MUC4 in metastasis of HNSCC is still unknown. Design: Sixteen cases of HNSCC with positive LN metastasis are retrieved from 2012 to 2015. Immunohistochemistry and Western blot were performed using mouse monoclonal antibody, clone 8G7, which recognizes human MUC4. HNSCC cell lines SCC1, SCC10B and SCC23 were used for in vitro study. The shMUC4 or a scrambled shRNA was transfected into cell lines to generate a stable knockdown of MUC4 (shMUC4) or a control (scrMUC4) using Lipofectamine 2000 (Invitrogen, CA). Results: Among the sixteen cases, 9 are originated from oral cavity, 3 from oropharynx, and 4 from larynx. The mean age is 62.2 years old ( from 50 to 76) with female to male ratio 1:1. The Immunohistochemical analysis showed significant upregulation of MUC4 in LN metastasis as compared to matched primary tumor (Fig. A) . In addition, MUC4 was highly upregulated in HNSCC cells under suspended condition (anoikis inducing condition), compared to attached cells suggesting that MUC4 plays an important role in protecting cells under anoikis condition (Fig. B) . Further, we developed anoikis resistant (AR) cells SCC1AR, SCC10BAR and SCC23AR from parental cells and observed upregulation of MUC4 in AR cells compared to the parental cells. The capacity of tumorigenesis, indicated by the size of colonies, correlates with the amount of MUC4 protein in different cell lines (Figs. C & D) . Stable knockdown of MUC4 in SCC1 and SCC10B cells resulted in sensitization to anoikis as evidenced by small colonies (Fig. E) . Conclusions: Our study revealed a novel function of MUC4 in protecting anoikis in HNSCC and suggested that MUC4 could be a promising candidate in therapy, especially in the inhibition of cancer metastasis. 
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